These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37163684)

  • 1. Personalized mRNA Vaccine Immunogenic against PDAC.
    Cancer Discov; 2023 Jul; 13(7):1504. PubMed ID: 37163684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
    Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
    Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
    Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
    Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma.
    Capretti G; Nebbia M; Gavazzi F; Nappo G; Ridolfi C; Sollai M; Spaggiari P; Bozzarelli S; Carrara S; Luberto A; Zerbi A
    Pancreatology; 2022 Sep; 22(6):782-788. PubMed ID: 35701318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
    Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
    Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
    Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
    Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of B cell transposition gene 3 in pancreatic ductal adenocarcinoma and its prognostic value].
    Chen J; Zhou ZC; Liu WB; Wang J; Chen XJ; Shen YY; Zhong ZX
    Zhonghua Wai Ke Za Zhi; 2017 Nov; 55(11):863-867. PubMed ID: 29136736
    [No Abstract]   [Full Text] [Related]  

  • 10. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
    Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
    Front Immunol; 2019; 10():1832. PubMed ID: 31440238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
    Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
    J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer.
    Zhang JF; Hua R; Sun YW; Liu W; Huo YM; Liu DJ; Li J
    Asian Pac J Cancer Prev; 2013; 14(9):5133-9. PubMed ID: 24175789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
    Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
    J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
    Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
    Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.
    Ferguson MD; Dong L; Wan J; Deneve JL; Dickson PV; Behrman SW; Shibata D; Martin MG; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):285-291. PubMed ID: 29427136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.
    Ling Q; Xu X; Ye P; Xie H; Gao F; Hu Q; Liu Z; Wei X; Röder C; Trauzold A; Kalthoff H; Zheng S
    Oncotarget; 2017 Feb; 8(9):15159-15167. PubMed ID: 28122349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma.
    Ye Y; Chen J; Zhou Y; Fu Z; Zhou Q; Wang Y; Gao W; Zheng S; Zhao X; Chen T; Chen R
    J Transl Med; 2015 Apr; 13():137. PubMed ID: 25925763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma.
    Groot VP; Daamen LA; Hagendoorn J; Borel Rinkes IHM; van Santvoort HC; Molenaar IQ
    J Surg Res; 2018 Jan; 221():152-160. PubMed ID: 29229122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.